News

Cases of COVID-19, RSV, and influenza are expected to rise this fall and winter season; yet, the number of people who plan on getting the vaccines for each of the infections remains low, according to the NFID announcement today.

Deborah Birx, MD, highlights concerns about the lack of data-driven action in the fight against COVID-19. She emphasizes the need for timely alerts and empowering communities to protect vulnerable individuals.

The AHE Exchange Conference in Dallas focused on emerging pathogens and the role of environmental services. Doe Kley, MPH, RN, T-CHEST, LTC-CIP, CIC, discusses her and other exceptional presentations with Infection Control Today.

Ambassador Deborah Birx, MD, discusses whether students should be required to wear masks to protect themselves and others and what the public should know about the newest COVID-19 variant, B.A.2.86.

Randomized controlled trials show masks are effective. With COVID-19, even one mistake in protective gear usage could lead to infection and obscure results.

In this Hot Topics in IPC, Saskia v. Popescu, PhD, MPH, MA, CIC, FAPIC, discusses COVID-19 vaccines and boosters, Legionella infections from transplants, and hospital leadership.

Besides its influenza pipeline, mRNA technology is helping this pharmaceutical company create a number of new vaccines for cancer, rare diseases, and infectious diseases.

Hepatitis C cases increased in 2021, while A and B decreased. The pandemic may have impacted the progress.

All eye drops from Dr. Berne’s Whole Health Products are being recalled after FDA warning on August 24. There are 2 adverse reactions reported so far.

This guide aims to assist hospitals in identifying and managing sepsis at an earlier stage. ICT interviews 1 of the authors.

Eagle Pharmaceuticals randomized its first patient in the Phase 2 study of CAL02, a safe and promising anti-toxin drug that treats severe community-acquired bacterial pneumonia without contributing to antibiotic resistance.

Take 5 minutes to catch up on Infection Control Today®’s highlights for the week ending Aug 20, 2023.

In this Hot Topics in IPC, Saskia v. Popescu, PhD, MPH, MA, CIC, gives the latest on COVID-19, tuberculosis, and changes in leadership at the CDC and NIAID.

Connecting and networking with colleagues, finding the right resources, and joining key organizations can help you become a better infection preventionist.

Take 5 minutes to catch up on Infection Control Today®’s highlights for the week ending July 30, 2023.

A new remote sexual health testing provider is available to US public health officials. It aims to reduce the increasing spread of sexually transmitted infections.

In this opinion article, the authors discuss their concerns about the recent HICPAC/CDC proposals on infectious diseases.

Neal Buchalter, MBA, president of Parker Laboratories, spoke with Infection Control Today® in an exclusive interview about the product, the companies involved, and how it came to the US market.

AstraZeneca's new drug, a monoclonal antibody, was given FDA approval after the Antimicrobial Drugs Advisory Committee (AMDAC) to the FDA voted in June to recommend the approval of nirsevimab (Beyfortus) for the prevention of respiratory syncytial virus (RSV) disease in infants.

In his analysis, Kevin Kavanagh, MD, explores the measures taken by the infectious disease sector in response to the pandemic, pointing out both effective and ineffective approaches. He also discusses how the pandemic has affected the treatment of other infectious diseases.

A small study explored the connection between Postural Orthostatic Tachycardia Syndrome (POTS) and the COVID-19 condition.

A session held at the APIC 2023 Annual Conference & Exhibition delved into the importance of equity in infection prevention and explored the impact of health inequities on the transmission of diseases.

Investigators studied 2 infants experiencing seizures, small head size, and developmental delays born of mothers who had contracted COVID-19 during pregnancy.

Legionnaires’ disease is a severe infection and fatal in 10% of cases.

Establishing a permanent system for monitoring the persistence and emergence of dangerous pathogens is necessary, especially COVID-19.

The vaccine is approved for use in adults aged 60 and older to prevent lower respiratory tract disease caused by RSV.

Saskia v. Popescu, PhD, MPH, MA, CIC, gives the latest on COVID-19, Marburg Virus Disease, and a 1-hit STI antibiotic plan.

Take 5 minutes to catch up on Infection Control Today®’s highlights for the week ending April 23, 2023.

Sulbactam-durlobactam is under priority review (PDUFA; May 29, 2023). 

Despite the recent CDC warning and frightening media coverage, understanding which patients are at a higher risk of Candida auris is important too. The lead author of the recent CDC's study spoke to ICT's sister brand for further insights on the threat.